Glaxo’s Avandia Faces Potential Recall in U.S. Advisers’ Vote

GlaxoSmithKline Plc’s Avandia may face tougher scrutiny from a U.S. advisory panel reviewing whether the diabetes pill should be pulled from the market than a similar analysis in 2007, doctors said.

Avandia was linked to heart attacks and other cardiovascular complications in two new studies published yesterday that the authors say should prompt U.S. regulators to block its sale. Outside advisers to the U.S. Food and Drug Administration will meet for two days beginning July 13 and are likely to consider whether the pill should remain on the market, deputy commissioner Joshua Sharfstein said.